Quadrant Capital Group LLC Has $171,000 Stock Holdings in Masimo Co. (NASDAQ:MASI)

Quadrant Capital Group LLC lowered its position in shares of Masimo Co. (NASDAQ:MASI) by 14.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,039 shares of the medical equipment provider’s stock after selling 169 shares during the quarter. Quadrant Capital Group LLC’s holdings in Masimo were worth $171,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in MASI. National Bank of Canada FI acquired a new stake in shares of Masimo during the 2nd quarter worth about $29,000. Caisse DE Depot ET Placement DU Quebec bought a new stake in Masimo during the 1st quarter worth about $37,000. Achmea Investment Management B.V. acquired a new stake in Masimo in the 2nd quarter valued at about $39,000. Trivant Custom Portfolio Group LLC bought a new position in shares of Masimo in the first quarter worth about $55,000. Finally, Massmutual Trust Co. FSB ADV lifted its position in shares of Masimo by 202.7% during the second quarter. Massmutual Trust Co. FSB ADV now owns 342 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 229 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Up 1.0 %

NASDAQ:MASI opened at $94.69 on Tuesday. Masimo Co. has a 12-month low of $75.22 and a 12-month high of $198.00. The company has a quick ratio of 1.13, a current ratio of 2.14 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $5.00 billion, a P/E ratio of 57.74 and a beta of 0.88. The stock’s fifty day simple moving average is $86.83 and its 200-day simple moving average is $122.29.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 7th. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Masimo had a return on equity of 14.18% and a net margin of 4.19%. The business had revenue of $478.90 million for the quarter, compared to analyst estimates of $498.73 million. During the same period last year, the company earned $1.00 EPS. The firm’s revenue was down 12.8% on a year-over-year basis. Equities research analysts expect that Masimo Co. will post 2.93 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MASI. Needham & Company LLC lowered their price target on shares of Masimo from $136.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Raymond James downgraded Masimo from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 8th. StockNews.com cut Masimo from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Wells Fargo & Company dropped their price objective on Masimo from $110.00 to $81.00 and set an “equal weight” rating for the company in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo presently has a consensus rating of “Hold” and a consensus price target of $122.00.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.